A股異動 | 新宙邦漲逾6% 一季度淨利潤預增40%-60%
格隆匯4月2日丨新宙邦(300037.SZ)現報38.11元,漲6.33%,暫成交2.82億元,最新總市值144億元。新宙邦昨晚披露2020年一季度業績預告稱,預計歸屬於上市公司股東的淨利潤8692.80萬元-9934.62萬元,同比增長40%-60%。業績變動原因如下:1、期內,預計公司主營業務利潤較上年同期上升,一方面是有機氟化學品海內外市場含氟醫藥、農藥中間體產品及環保型含氟表面活性劑銷量大幅增長;另一方面是鋰電池化學品國際客户訂單增長;此外,電容器化學品、半導體化學品業務保持穩定。2、期內公司非經常性損益約為200萬元,與上年同期持平,不構成本期淨利潤的重要組成部分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.